Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK)
HKD 0.67
(0.0%)
HKD 0.67
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 161.69 Million CNY | 130.17% |
| 2022 | -536.02 Million CNY | -179.27% |
| 2021 | 676.19 Million CNY | 39.19% |
| 2020 | 485.81 Million CNY | -65.16% |
| 2019 | 1.39 Billion CNY | -19.09% |
| 2018 | 1.72 Billion CNY | 17.65% |
| 2017 | 1.46 Billion CNY | -24.3% |
| 2016 | 1.93 Billion CNY | -6.71% |
| 2015 | 2.07 Billion CNY | 4.83% |
| 2014 | 1.97 Billion CNY | 35.36% |
| 2013 | 1.46 Billion CNY | 39.54% |
| 2012 | 1.04 Billion CNY | 5.8% |
| 2011 | 990.34 Million CNY | 61.48% |
| 2010 | 613.31 Million CNY | 64.42% |
| 2009 | 373.02 Million CNY | 24.13% |
| 2008 | 300.52 Million CNY | 62.77% |
| 2007 | 184.62 Million CNY | 69.61% |
| 2006 | 108.85 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 109.1 Million CNY | 0.0% |
| 2023 FY | 161.69 Million CNY | 130.17% |
| 2023 Q2 | 60.5 Million CNY | 0.0% |
| 2023 Q4 | 15.53 Million CNY | 0.0% |
| 2022 FY | -536.02 Million CNY | -179.27% |
| 2022 Q2 | 74.65 Million CNY | 0.0% |
| 2021 FY | 676.19 Million CNY | 39.19% |
| 2021 Q2 | 751.18 Million CNY | 0.0% |
| 2020 Q2 | 247.92 Million CNY | 0.0% |
| 2020 Q4 | 237.89 Million CNY | 0.0% |
| 2020 FY | 485.81 Million CNY | -65.16% |
| 2019 Q4 | 357.9 Million CNY | 0.0% |
| 2019 Q2 | 1.03 Billion CNY | 0.0% |
| 2019 FY | 1.39 Billion CNY | -19.09% |
| 2018 FY | 1.72 Billion CNY | 17.65% |
| 2018 Q4 | 861.54 Million CNY | 0.0% |
| 2018 Q2 | 862.05 Million CNY | 0.0% |
| 2017 Q2 | 797.92 Million CNY | 0.0% |
| 2017 Q4 | 667.08 Million CNY | 0.0% |
| 2017 FY | 1.46 Billion CNY | -24.3% |
| 2016 Q2 | 828.14 Million CNY | 0.0% |
| 2016 FY | 1.93 Billion CNY | -6.71% |
| 2016 Q4 | 1.1 Billion CNY | 0.0% |
| 2015 Q4 | 1.02 Billion CNY | 0.0% |
| 2015 FY | 2.07 Billion CNY | 4.83% |
| 2015 Q2 | 1.05 Billion CNY | 0.0% |
| 2014 FY | 1.97 Billion CNY | 35.36% |
| 2014 Q4 | 1.01 Billion CNY | 0.0% |
| 2014 Q2 | 962.32 Million CNY | 0.0% |
| 2013 FY | 1.46 Billion CNY | 39.54% |
| 2013 Q4 | 853.24 Million CNY | 117.6% |
| 2013 Q3 | 392.1 Million CNY | -39.09% |
| 2013 Q2 | 643.79 Million CNY | 64.19% |
| 2013 Q1 | 392.1 Million CNY | 0.0% |
| 2012 Q4 | 392.1 Million CNY | 35.75% |
| 2012 FY | 1.04 Billion CNY | 5.8% |
| 2012 Q2 | 288.84 Million CNY | 0.0% |
| 2012 Q1 | 288.84 Million CNY | 0.0% |
| 2012 Q3 | 288.84 Million CNY | 0.0% |
| 2011 Q4 | 288.84 Million CNY | 7.91% |
| 2011 Q3 | 267.68 Million CNY | 0.0% |
| 2011 Q2 | 267.68 Million CNY | 0.0% |
| 2011 Q1 | 267.68 Million CNY | 0.0% |
| 2011 FY | 990.34 Million CNY | 61.48% |
| 2010 Q4 | 267.68 Million CNY | 64.2% |
| 2010 FY | 613.31 Million CNY | 64.42% |
| 2010 Q1 | 163.02 Million CNY | 0.0% |
| 2010 Q2 | 163.02 Million CNY | 0.0% |
| 2010 Q3 | 163.02 Million CNY | 0.0% |
| 2009 Q4 | 163.02 Million CNY | 65.39% |
| 2009 FY | 373.02 Million CNY | 24.13% |
| 2009 Q3 | 98.56 Million CNY | 0.0% |
| 2009 Q2 | 98.56 Million CNY | 0.0% |
| 2009 Q1 | 98.56 Million CNY | 0.0% |
| 2008 Q3 | 73.51 Million CNY | 0.0% |
| 2008 Q1 | 73.51 Million CNY | 0.0% |
| 2008 FY | 300.52 Million CNY | 62.77% |
| 2008 Q2 | 73.51 Million CNY | 0.0% |
| 2008 Q4 | 98.56 Million CNY | 34.08% |
| 2007 Q2 | 46.26 Million CNY | 0.0% |
| 2007 Q1 | 46.26 Million CNY | 0.0% |
| 2007 Q3 | 46.26 Million CNY | 0.0% |
| 2007 FY | 184.62 Million CNY | 69.61% |
| 2007 Q4 | 73.51 Million CNY | 58.9% |
| 2006 FY | 108.85 Million CNY | 0.0% |
| 2006 Q1 | 27.28 Million CNY | 0.0% |
| 2006 Q3 | 27.28 Million CNY | 0.0% |
| 2006 Q4 | 46.26 Million CNY | 69.58% |
| 2006 Q2 | 27.28 Million CNY | 0.0% |
| 2005 Q4 | 27.28 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | -13.066% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 93.929% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 2081.108% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | -295.543% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 409.867% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -348.638% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 47.895% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 344.826% |
| SSY Group Limited | 1.63 Billion HKD | 90.134% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 7.179% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 51.46% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 98.669% |